Chronic Pulmonary Hypertension Treatment Market

Chronic pulmonary hypertension treatment sales will expand through 2036, with endothelin receptor antagonists holding 36.9% of the drug type in 2026. The market was valued at USD 7.75 billion in 2025 and is expected to be worth USD 13.20 billion by 2036, creating an incremental opportunity of USD 5.10 billion.